Literature DB >> 12622521

The impact of TNF-alpha induction on therapeutic efficacy following high dose spatially fractionated (GRID) radiation.

Sabapathi Sathishkumar1, Swatee Dey, Ali S Meigooni, William F Regine, Mahesh S Kudrimoti, Mansoor M Ahmed, Mohammed Mohiuddin.   

Abstract

A variety of cytokines especially TNF-alpha and TGF-beta are known to be released in response to high dose radiation of tumors. However, these are not normally measurable in systemic circulation unless high levels of these cytokines are produced by tumor cells. This study was undertaken to see if circulating levels of these cytokines could be measured in the serum of patients treated with high dose spatially fractionated (GRID) radiation and to correlate the finding of these cytokines with clinical response to treatment. Thirty-four patients (31 patients had single treatment site and 3 patients had 2 treatment sites) treated with spatially fractionated (GRID) radiation were entered in this study. Serum samples were collected before treatment and at 24, 48 and 72 hours after GRID radiation. Sandwich enzyme linked immunosorbent assay (ELISA) was performed to estimate the levels of TNF-alpha and activated TGF-beta1 proteins. Seven of 37 patients studied had no TNF-alpha protein before treatment but showed induction of TNF-alpha after GRID radiation. Three patients showed faint basal level of TNF-alpha protein before treatment and these levels were induced after treatment. Three patients showed a basal level of TNF-alpha protein before treatment and these levels decreased after treatment. In 21 cases no TNF-alpha protein was detected before or after treatment at the time points measured. In the case of TGF-beta1 protein, 2 patients showed no TGF-beta1 protein before GRID radiation and an induction of TGF-beta1 protein was observed after treatment. Seven patients showed basal level of TGF-beta1 protein prior to treatment and these levels were induced after treatment. Seventeen patients showed a basal level of TGF-beta1 protein before treatment and these levels decreased after treatment. In 8 cases no TGF-beta1 protein was detected before or after treatment. Complete clinical response (CR) to GRID therapy was seen in 12/37 (32%) treatment sites and partial response (PR) in 18/37 (49%) treatment sites. A strong correlation was observed between clinical CR rate and TNF-alpha induction. The rate of CR was 6/10 (60%) in patients where TNF-alpha was induced as compared to 6/27 (23%) treatment sites in patients where TNF-alpha induction was not seen (p = 0.029). No significant correlation with CR rate and TGF-beta1 induction (44% vs. 28%, p = 0.36) was observed. High dose spatially fractionated (GRID) radiation results in significant induction of TNF-alpha that can be measured in serum of some patients 24 72 hours after radiation. Complete tumor response strongly correlated with the induction of TNF-alpha levels in the serum.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12622521     DOI: 10.1177/153303460200100207

Source DB:  PubMed          Journal:  Technol Cancer Res Treat        ISSN: 1533-0338


  25 in total

Review 1.  Exploiting sensitization windows of opportunity in hyper and hypo-fractionated radiation therapy.

Authors:  Anish Prasanna; Mansoor M Ahmed; Mohammed Mohiuddin; C Norman Coleman
Journal:  J Thorac Dis       Date:  2014-04       Impact factor: 2.895

2.  Role of Radiation-induced TGF-beta Signaling in Cancer Therapy.

Authors:  Horatiu C Dancea; Mohammed M Shareef; Mansoor M Ahmed
Journal:  Mol Cell Pharmacol       Date:  2009

3.  Stereotactic Ablative Radiotherapy (SABR): Impact on the Immune System and Potential for Future Therapeutic Modulation.

Authors:  Adam S Reese; Steven J Feigenberg; Azmat Husain; Tonya J Webb; Petr F Hausner; Martin J Edelman; Josephine Feliciano; Katherine H Tkaczuk; Navesh K Sharma
Journal:  Mol Cell Pharmacol       Date:  2013-01-01

4.  Radiation-Induced Fibrosis: Mechanisms and Opportunities to Mitigate. Report of an NCI Workshop, September 19, 2016.

Authors:  Deborah E Citrin; Pataje G S Prasanna; Amanda J Walker; Michael L Freeman; Iris Eke; Mary Helen Barcellos-Hoff; Molykutty J Arankalayil; Eric P Cohen; Ruth C Wilkins; Mansoor M Ahmed; Mitchell S Anscher; Benjamin Movsas; Jeffrey C Buchsbaum; Marc S Mendonca; Thomas A Wynn; C Norman Coleman
Journal:  Radiat Res       Date:  2017-05-10       Impact factor: 2.841

5.  Effective spatially fractionated GRID radiation treatment planning for a passive grid block.

Authors:  A Nobah; M Mohiuddin; S Devic; B Moftah
Journal:  Br J Radiol       Date:  2015-01       Impact factor: 3.039

6.  Spatially fractionated radiation induces cytotoxicity and changes in gene expression in bystander and radiation adjacent murine carcinoma cells.

Authors:  Rajalakshmi S Asur; Sunil Sharma; Ching-Wei Chang; Jose Penagaricano; Indira M Kommuru; Eduardo G Moros; Peter M Corry; Robert J Griffin
Journal:  Radiat Res       Date:  2012-05-04       Impact factor: 2.841

7.  The dosimetric enhancement of GRID profiles using an external collimator in pencil beam scanning proton therapy.

Authors:  Blake R Smith; Nicholas P Nelson; Theodore J Geoghegan; Kaustubh A Patwardhan; Patrick M Hill; Jen Yu; Alonso N Gutiérrez; Bryan G Allen; Daniel E Hyer
Journal:  Med Phys       Date:  2022-02-21       Impact factor: 4.071

8.  In vivo effects of lattice radiation therapy on local and distant lung cancer: potential role of immunomodulation.

Authors:  Saravana Kanagavelu; Seema Gupta; Xiaodong Wu; Sakhi Philip; Max M Wattenberg; James W Hodge; Mariluz D Couto; Kristina D Chung; Mansoor M Ahmed
Journal:  Radiat Res       Date:  2014-07-18       Impact factor: 2.841

Review 9.  A Current Review of Spatial Fractionation: Back to the Future?

Authors:  Cole Billena; Atif J Khan
Journal:  Int J Radiat Oncol Biol Phys       Date:  2019-01-23       Impact factor: 7.038

Review 10.  High dose bystander effects in spatially fractionated radiation therapy.

Authors:  Rajalakshmi Asur; Karl T Butterworth; Jose A Penagaricano; Kevin M Prise; Robert J Griffin
Journal:  Cancer Lett       Date:  2013-11-15       Impact factor: 8.679

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.